Benchmarking Meta-Analysis of New-Product Bridge and Fast-Start Patient Assistance Programs

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Biopharmaceutical; Laboratories; Clinical Research; Manufacturing; Consumer Products; Service; Science; Consulting; Chemical; Public Relations; Technology; Communications; Utilities; Computer Software; Telecommunications; Research; Market Research; Medical; Professional Services; Marketing


Companies Profiled:
Abbott; AbbVie; Actelion; Adamas Pharmaceuticals; ADC Therapeutics; Advanced Accelerator Applications; Advanced Sterilization Products; Aerocrine; AeroGen; Agenus; Agios; Aimmune Therapeutics; Akcea Therapeutics; Alcon; Alexion Pharmaceuticals; Align Technology; Alkem; Alkermes; Allergan; Almirall; Alnylam Pharmaceuticals; Altus Biologics; AMAG Pharmaceuticals; Amgen; Amicus Therapeutics; Amylin; Apellis Pharmaceuticals; Aptus Clinical; Arena Pharmaceuticals; Ascend Therapeutics; Ascensia; Asklepion Pharmaceuticals; Aspen Pharmacare; Astellas; AstraZeneca; Atara Biotherapeutics; Auxilium; Avadel Pharmaceuticals; Avanir; Avant Healthcare; Avantor Performance Materials; Aventis; B. Braun; Baxter International; Bayer; Becton Dickinson; BioDelivery Sciences International; Biofrontera; Biogen; Bionical Solutions; Biosense Webster; Boehringer Ingelheim; Boston Scientific; Bracco Diagnostics Inc.; Braeburn; Bristol-Myers Squibb; BSN medical; Canopy Growth; Cara Therapeutics; CardioDynamics; CareFusion; Cascadia Drug Development Group; Catalent Pharma Solutions; Catalyst Pharmaceuticals; Celgene; Celyad; Centocor Ortho Biotech Inc.; Centurion; Chiesi; Cipla; Cofactor Group; Consensus Orthopedics; CooperVision; Cordis; Covidien; CSL Behring; Cubist Pharmaceuticals; Cutanea Life Sciences; Cytokinetics; Daiichi Sankyo; DBV Tehcnologies; Deciphera Pharmaceuticals; Dendreon Pharmaceuticals LLC; DiaSorin; Dicerna Pharmaceuticals; Dr Reddy's Laboratories; Drager; Eagle Pharmaceuticals; EHOB; Eisai; Eli Lilly and Company; Elixir Pharmaceuticals; EMD Serono; Endo Health Solutions; eNeura Therapeutics; Entelos; Envision Pharma Group; Ethicon; Ethypharm; EyePoint Pharmaceuticals; F1 Oncology; FerGene; Ferozsons Laboratories Limited; Ferring Pharmaceuticals; FleishmanHillard; Forest Laboratories; Foundation Medicine; Frankel Advisory Group LLC; Fresenius Medical Care AG & Co. KGaA; Galderma; Galpha Laboratories; GE Healthcare; Genentech; Genmab; Genzyme; Getz Pharma; Gilead Sciences; GlaxoSmithKline ; Glenmark; Greenwich Biosciences; Grifols; Grünenthal; Guerbet; Halloran Consulting Group; Helsinn; Hikma; HLL Lifecare; Hoffmann-La Roche; Horizon Therapeutics; Human Genome Sciences; IDbyDNA; Idorsia; IMS; Incyte; Indivior; Inspire Pharmaceuticals; Intervet International (part of Schering-Plough); Invive Healthcare; Ipsen; Iridex; Ironwood; Janssen; Joerns Healthcare; Johnson & Johnson; Kadmon Pharmaceuticals; Kala Pharmaceuticals; Kaleo; Karyopharm Therapeutics; KimberlyClark; Kiniksa Pharmaceuticals; Kyowa Kirin; Leica Biosystems; LeMaitre Vascular; LEO Pharma; Lexicon Pharmaceuticals; Lilly; Lumenis; Lundbeck; Lupin; Mallinckrodt; Mayne Pharma; McKesson (Patient Relationship Solutions); Meda Pharmaceuticals; Medacta USA; Medexus Pharmaceuticals; Medicago; Medicure; MedinCell; MEDiSTRAVA; Medivation; Medline; Medrad; Medrobotics; Medtronic; Melinta Therapeutics; Menarini Group; Merck; Merck KGaA; Merck Serono; Micro Labs; Milestone Pharmaceuticals; Mint Pharmaceuticals Inc.; Mirador Global LP; Mission Bio; Monebo Technologies; Monogram Biosciences; MSD; Mylan; Myovant Sciences; Nabriva Therapeutics; Nektar Therapeutics; Nestle Health Science; Neurocrine Biosciences; Nevakar; NexGen Healthcare Communications; Nico ; Nobio; Nonin; Novartis; Novartis Consumer Health; Noven Pharmaceuticals; Noven Therapeuticals; Novo Nordisk; Nuvisan; OncoCyte; Ora; Ortho Biotech; Ortho-Clinical Diagnostics; Osmotica Pharmaceuticals; OTSUKA; Panacea Biotec; PanTheryx; Paratek Pharmaceuticals; Parexel; Patheon; Pfizer; Pharmacyclics; Piramal Group; PLIVA Pharmaceuticals; Prime Global; Prometheus Therapeutics & Diagnostics; Proteus Digital Health; Purdue Pharma; QED Therapeutics; Ranbaxy; RECKITT BENCKISER; Regeneron; Retrophin; Rigel Pharmaceuticals; Roche; Roche Diagnostics; S3 Group; Samumed; Sandoz; Sanofi; Sanofi Genzyme; Sanofi Pasteur; Sanofi-Aventis; Santen; Santhera Pharmaceuticals; Sarah Cannon; Schering-Plough; Scilex Pharmaceuticals; Sebela; Servier; Shionogi Inc.; Shire; Siren Interactive; Sivantos Pte. Ltd.; SK Life Science; Smith & Nephew; Solvay Pharmaceuticals; SomaGenics Inc; Stgilesmedical London & Berlin; Stiefel; Straumann; Stryker; Sumitovant BioPharma; Sunovion; Supernus; Surrozen; Syneos Health; Syros Pharmaceuticals; Takeda Oncology; Takeda Pharmaceuticals; Tecan; TerSera Therapeutics; Tesaro; Teva Neuroscience; Teva Pharmaceutical Industries Ltd; TG Therapeutics; The Medical Affairs Company; The Stem; Theravance; Thermo Fisher Scientific; Think Surgical; Thompson Surgical Instruments; Tokai Pharmaceuticals; UCB Pharma; United BioSource; United Therapeutics; Valeant; Vertex Pharmaceuticals; Victory; Vifor Pharma; ViiV Healthcare; Visioneering Technologies Inc.; Wellspect HealthCare; West 53rd St Digital; Wockhardt; Worldwide Clinical Trials; XACT Robotics; Xanodyne Pharmaceuticals; XG Sciences; Zeiss Pharma; Zimmer Biomet; Zoetis Inc.; Zosano Pharma; ZS Pharma; Zydus Cadila

Study Snapshot

This Best Practices, LLC report draws upon 9 of our benchmarking field studies of over 300 companies probing bridge and other patient assistance programs.

Key topics covered in this report include:

• Current trends and future directions of bridge assistance programs supporting new biopharmaceutical products
• Prevalence and impact of bridge programs
• Bridge programs role during new product introduction
• Patient support hub vendor management
• Patient support hub services
• Pull through framework

• Multi-faceted Programs: Deployed by 53% of companies – bridge programs are part of multi-faceted patient support systems that provide upfront and continuous services

• Risk of Doing Nothing: 92% of organizations consider Patient Support Failures to be a high- or medium-risk pitfall: patients that have difficulty getting started are easily lost for good

• One of Many: Fast Start Programs are one of 15 patient support services often coordinated through Hubs

• Utilization of bridge programs - Breakdown by therapeutic area
• Observed impact of listed patient assistance programs in response to the COVID-19 crisis
• Impact of patient support/assistance programs
• Frontline tactics to ensure fast early coverage and continued access to treatment for patients already impacted
• Current and future risk level of each patient pitfall that can derail a new product coming into a crowded market
• Collaboration with patient hub vendor; Patient support hub offerings
• Patient support hub packages / services
• Evolution of patient assistance / support programs during COVID-19 crisis
• Pull through excellence to support bridge / fast start and other patient programs